World Journal of Emergency Medicine ›› 2025, Vol. 16 ›› Issue (6): 597-602.doi: 10.5847/wjem.j.1920-8642.2025.117
• Research Letters • Previous Articles Next Articles
Open Access
Shenglan Liu1, Hua Xu1, Zhengyan Wu2, Yanxia Guo1, Zheng Fan1, Yuanyuan Zhang1, Lichao Fang3(
), Weichang Chen4()
Received:2025-01-06
Accepted:2025-05-26
Online:2025-11-13
Published:2025-11-01
Contact:
Lichao Fang, Email: lichaofang76@163.comShenglan Liu, Hua Xu, Zhengyan Wu, Yanxia Guo, Zheng Fan, Yuanyuan Zhang, Lichao Fang, Weichang Chen. Plasma metabolomic analysis of patients with different severities acute pancreatitis[J]. World Journal of Emergency Medicine, 2025, 16(6): 597-602.
Add to citation manager EndNote|Ris|BibTeX
URL: http://wjem.com.cn/EN/10.5847/wjem.j.1920-8642.2025.117
Figure 1.
Orthogonal projection to latent structures squares-discriminant analysis (OPLS-DA) score plot (A) and the T-prediction score of the test set (B). Blue triangle: training set of Pcontrol; red triangle: training set of PSAP; green triangle: training set of PMAP; blue square: test set of Pcontrol; red square: test set of PSAP; green square: test set of PMAP.
Table 1
The clinical diagnostic value of identified metabolites
| Metabolites | SAP vs control | MAP vs control | SAP vs MAP | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIP | P-value | AUC | Fold change | VIP | P-value | AUC | Fold change | VIP | P-value | AUC | Fold change | |||
| D(-)-beta-hydroxybutyric acid | 1.150 | 0.000 | 0.863 | 7.600 | 1.020 | 0.000 | 0.845 | 18.200 | 1.570 | 0.123 | 0.583 | 0.417 | ||
| L-leucine | 0.413 | 0.568 | 0.546 | 1.180 | 0.987 | 0.000 | 0.793 | 1.610 | 1.300 | 0.004 | 0.687 | 0.731 | ||
| Indolelactic acid | 0.965 | 0.000 | 0.816 | 3.210 | 0.671 | 0.028 | 0.642 | 1.660 | 1.560 | 0.017 | 0.646 | 1.940 | ||
| Nonanedioic acid | 1.270 | 0.000 | 0.826 | 3.050 | 1.260 | 0.000 | 0.844 | 3.610 | 0.670 | 0.269 | 0.573 | 0.845 | ||
| Glyceric acid | 1.080 | 0.000 | 0.868 | 3.960 | 0.967 | 0.000 | 0.867 | 3.920 | 0.028 | 0.983 | 0.498 | 1.010 | ||
| Threonate | 0.948 | 0.000 | 0.795 | 7.320 | 0.454 | 0.300 | 0.573 | 2.190 | 1.760 | 0.001 | 0.717 | 3.340 | ||
| 3-buten-1-amine | 0.511 | 0.110 | 0.611 | 1.150 | 0.987 | 0.000 | 0.769 | 1.550 | 1.450 | 0.008 | 0.652 | 0.741 | ||
| 4-hydroxy benzenesulfonic acid | 0.641 | 0.315 | 0.554 | 3.110 | 0.187 | 0.052 | 0.617 | 0.750 | 1.640 | 0.009 | 0.666 | 4.150 | ||
| L-glutamine | 1.190 | 0.000 | 0.800 | 1.950 | 1.260 | 0.000 | 0.848 | 2.040 | 0.230 | 0.542 | 0.541 | 0.954 | ||
| L-histidine | 1.080 | 0.000 | 0.821 | 2.190 | 0.903 | 0.000 | 0.780 | 2.540 | 0.416 | 0.814 | 0.527 | 0.861 | ||
| L-glutamate | 1.030 | 0.000 | 0.798 | 3.850 | 1.130 | 0.000 | 0.837 | 3.940 | 0.062 | 0.606 | 0.561 | 0.976 | ||
| Sphinganine | 0.982 | 0.001 | 0.760 | 0.879 | 0.042 | 0.478 | 0.542 | 0.995 | 1.680 | 0.002 | 0.689 | 0.884 | ||
| Hexadecanedioic acid | 1.040 | 0.000 | 0.900 | 12.700 | 0.634 | 0.000 | 0.794 | 12.200 | 0.051 | 0.059 | 0.619 | 1.030 | ||
| Creatinine | 0.430 | 0.449 | 0.569 | 1.720 | 0.804 | 0.005 | 0.705 | 0.769 | 1.230 | 0.001 | 0.705 | 2.230 | ||
| Oxoglutaric acid | 1.070 | 0.000 | 0.958 | 15.500 | 0.954 | 0.000 | 0.925 | 11.800 | 0.569 | 0.324 | 0.575 | 1.320 | ||
| L-tryptophan | 0.676 | 0.005 | 0.702 | 0.722 | 0.280 | 0.618 | 0.529 | 1.200 | 1.500 | 0.004 | 0.666 | 0.602 | ||
| Indoxylsulfuric acid/3-Indoxyl sulfate | 0.482 | 0.420 | 0.558 | 8.240 | 0.313 | 0.033 | 0.648 | 0.696 | 1.200 | 0.003 | 0.688 | 11.800 | ||
| Angelic acid | 1.160 | 0.000 | 0.812 | 1.810 | 1.100 | 0.000 | 0.798 | 2.540 | 1.120 | 0.202 | 0.577 | 0.715 | ||
| Malic acid | 1.360 | 0.000 | 0.974 | 17.400 | 1.090 | 0.000 | 0.944 | 10.000 | 1.410 | 0.048 | 0.637 | 1.740 | ||
| Creatine | 0.754 | 0.001 | 0.742 | 3.250 | 1.250 | 0.000 | 0.835 | 2.290 | 0.708 | 0.466 | 0.548 | 1.420 | ||
| L-valine | 0.625 | 0.052 | 0.629 | 1.720 | 0.939 | 0.000 | 0.798 | 3.200 | 1.270 | 0.010 | 0.649 | 0.538 | ||
| Acetylcarnitine | 1.390 | 0.000 | 0.924 | 3.780 | 1.540 | 0.000 | 0.934 | 3.220 | 0.630 | 0.405 | 0.548 | 1.170 | ||
| beta-Alanine | 1.190 | 0.000 | 0.773 | 1.880 | 0.785 | 0.009 | 0.685 | 1.710 | 0.352 | 0.148 | 0.588 | 1.100 | ||
| (R)-(+)-2-pyrrolidone-5-carboxylic acid | 1.440 | 0.000 | 0.968 | 4.090 | 1.530 | 0.000 | 0.957 | 3.410 | 0.712 | 0.386 | 0.576 | 1.200 | ||
| L-carnitine | 0.934 | 0.000 | 0.818 | 1.990 | 1.010 | 0.001 | 0.734 | 1.350 | 1.360 | 0.040 | 0.633 | 1.470 | ||
| Succinic aldehyde | 1.020 | 0.000 | 0.929 | 7.180 | 1.080 | 0.000 | 0.897 | 12.900 | 1.050 | 0.168 | 0.597 | 0.559 | ||
| L-phenylalanine | 1.290 | 0.000 | 0.910 | 1.840 | 1.000 | 0.000 | 0.811 | 1.670 | 0.434 | 0.094 | 0.592 | 1.100 | ||
| 2-aminoisobutyric acid | 0.851 | 0.007 | 0.699 | 1.740 | 1.200 | 0.000 | 0.858 | 2.570 | 1.260 | 0.003 | 0.685 | 0.677 | ||
| Uric acid | 1.680 | 0.000 | 0.946 | 4.340 | 1.470 | 0.000 | 0.920 | 3.100 | 1.640 | 0.007 | 0.678 | 1.400 | ||
| (S)-(-)-2-hydroxy isocaproic acid | 0.961 | 0.000 | 0.878 | 5.510 | 1.120 | 0.000 | 0.856 | 4.190 | 0.640 | 0.801 | 0.504 | 1.310 | ||
| Kynurenine | 1.270 | 0.000 | 0.833 | 3.100 | 0.620 | 0.013 | 0.680 | 1.830 | 1.400 | 0.001 | 0.722 | 1.690 | ||
| N,N-dimethylglycine | 0.851 | 0.007 | 0.698 | 1.740 | 1.200 | 0.000 | 0.866 | 2.570 | 1.260 | 0.003 | 0.690 | 0.677 | ||
| Sphingosine-1-phosphate | 0.823 | 0.006 | 0.695 | 1.850 | 1.350 | 0.000 | 0.838 | 2.370 | 0.884 | 0.016 | 0.674 | 0.780 | ||
| L-palmitoylcarnitine | 1.170 | 0.000 | 0.922 | 10.900 | 1.090 | 0.000 | 0.900 | 6.910 | 0.979 | 0.064 | 0.625 | 1.580 | ||
| Octanoylcarnitine | 0.972 | 0.000 | 0.850 | 7.870 | 0.527 | 0.000 | 0.805 | 2.100 | 1.790 | 0.000 | 0.766 | 3.750 | ||
| 1 |
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62(1): 102-11.
doi: 10.1136/gutjnl-2012-302779 |
| 2 |
Tenner S, Baillie J, DeWitt J, Vege SS;American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013; 108(9): 1400-15;1416.
doi: 10.1038/ajg.2013.218 pmid: 23896955 |
| 3 |
Padhan RK, Jain S, Agarwal S, Harikrishnan S, Vadiraja P, Behera S, et al. Primary and secondary organ failures cause mortality differentially in acute pancreatitis and should be distinguished. Pancreas. 2018; 47(3): 302-7.
doi: 10.1097/MPA.0000000000000998 |
| 4 |
Sternby H, Bolado F, Canaval-Zuleta HJ, Marra-López C, Hernando-Alonso AI, Del-Val-Antoñana A, et al. Determinants of severity in acute pancreatitis: a nation-wide multicenter prospective cohort study. Ann Surg. 2019; 270(2): 348-55.
doi: 10.1097/SLA.0000000000002766 pmid: 29672416 |
| 5 |
Schepers NJ, Bakker OJ, Besselink MG, Ali UA, Bollen TL, Gooszen HG, et al. Impact of characteristics of organ failure and infected necrosis on mortality in necrotising pancreatitis. Gut. 2019; 68(6): 1044-51.
doi: 10.1136/gutjnl-2017-314657 pmid: 29950344 |
| 6 |
Shi N, Liu TT, de la Iglesia-Garcia D, Deng LH, Jin T, Lan L, et al. Duration of organ failure impacts mortality in acute pancreatitis. Gut. 2020; 69(3): 604-5.
doi: 10.1136/gutjnl-2019-318241 pmid: 31233394 |
| 7 |
van den Berg FF, de Bruijn AC, van Santvoort HC, Issa Y, Boermeester MA. Early laboratory biomarkers for severity in acute pancreatitis; A systematic review and meta-analysis. Pancreatology. 2020; 20(7): 1302-11.
doi: 10.1016/j.pan.2020.09.007 pmid: 32938552 |
| 8 |
Ramirez T, Daneshian M, Kamp H, Bois FY, Clench MR, Coen M, et al. Metabolomics in toxicology and preclinical research. ALTEX. 2013; 30(2): 209-25.
doi: 10.14573/altex.2013.2.209 pmid: 23665807 |
| 9 |
Peng Y, Hong J, Raftery D, Xia Q, Du D. Metabolomic-based clinical studies and murine models for acute pancreatitis disease: a review. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(7): 166123.
doi: 10.1016/j.bbadis.2021.166123 |
| 10 |
Xiao H, Huang JH, Zhang XW, Ahmed R, Xie QL, Li B, et al. Identification of potential diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles. Pancreatology. 2017; 17(4): 543-9.
doi: S1424-3903(17)30081-9 pmid: 28487129 |
| 11 | Li MJ, Wang XF, Aa JY, Qin WS, Zha WB, Ge YC, et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am J Physiol Renal Physiol. 2013; 304(11): F1317-F1324. |
| 12 |
Houten SM, Wanders RJA, Ranea-Robles P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(5): 165720.
doi: 10.1016/j.bbadis.2020.165720 |
| 13 |
McCoin CS, Knotts TA, Adams SH. Acylcarnitines—old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol. 2015; 11(10): 617-25.
doi: 10.1038/nrendo.2015.129 pmid: 26303601 |
| 14 | Ge J, Guo JJ, Zhang X, Yang WZ, Han LS, Sun HZ, et al. L-palmitoylcarnitine supplementation improves oocyte quality and embryo development derived from obese mice. Fundamental Research. 2024. |
| 15 |
Bando M, Iwakura H, Koyama H, Hosoda H, Shigematsu Y, Ariyasu H, et al. High incorporation of long-chain fatty acids contributes to the efficient production of acylated ghrelin in ghrelin-producing cells. FEBS Lett. 2016; 590(7): 992-1001.
doi: 10.1002/1873-3468.12132 pmid: 26991015 |
| 16 |
Dholakia S, Sharples EJ, Ploeg RJ, Friend PJ. Significance of steatosis in pancreatic transplantation. Transplant Rev (Orlando). 2017; 31(4): 225-31.
doi: 10.1016/j.trre.2017.08.001 |
| 17 |
Kaya I, Citil M, Sozmen M, Karapehlivan M, Cigsar G. Investigation of protective effect of L-carnitine on L-asparaginase-induced acute pancreatic injury in male Balb/c mice. Dig Dis Sci. 2015; 60(5): 1290-6.
doi: 10.1007/s10620-014-3461-3 |
| 18 | Karakahya M, Gül M, Işık S, Aydın C, Yiğitcan B, Otan E, et al. The histopathologic effects of L-carnitine in sodium taurocholate induced severe pancreatitis model. Int Surg. 2016. Online ahead of print. |
| 19 |
Arafa HMM, Hemeida RAM, Hassan MIA, Abdel-Wahab MH, Badary OA, Hamada FMA. Acetyl-L-carnitine ameliorates caerulein-induced acute pancreatitis in rats. Basic Clin Pharmacol Toxicol. 2009; 105(1): 30-6.
doi: 10.1111/pto.2009.105.issue-1 |
| 20 | Kumar A, Bachhawat A. Pyroglutamic acid: throwing light on a lightly studied metabolite. Current Science. 2012; 102(2):288-97. |
| 21 |
Peris-Fernández M, Roca-Marugán M, Amengual JL, Balaguer-Timor Á, Viejo-Boyano I, Soldevila-Orient A, et al. Uremic toxins and inflammation: metabolic pathways affected in non-dialysis-dependent stage 5 chronic kidney disease. Biomedicines. 2024; 12(3): 607.
doi: 10.3390/biomedicines12030607 |
| 22 | Mutsaers HAM, Engelke UFH, Wilmer MJG, Wetzels JFM, Wevers RA, van den Heuvel LP, et al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients. PLoS One. 2013; 8(8): e71199. |
| 23 |
Mole DJ, McFerran NV, Collett G, O’Neill C, Diamond T, Garden OJ, et al. Tryptophan catabolites in mesenteric lymph may contribute to pancreatitis-associated organ failure. Br J Surg. 2008; 95(7): 855-67.
doi: 10.1002/bjs.6112 pmid: 18473343 |
| 24 |
Mole DJ, Webster SP, Uings I, Zheng XZ, Binnie M, Wilson K, et al. Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat Med. 2016; 22(2): 202-9.
doi: 10.1038/nm.4020 pmid: 26752518 |
| 25 |
Liddle J, Beaufils B, Binnie M, Bouillot A, Denis AA, Hann MM, et al. The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis. Bioorg Med Chem Lett. 2017; 27(9): 2023-8.
doi: S0960-894X(17)30221-4 pmid: 28336141 |
| 26 |
Walker AL, Ancellin N, Beaufils B, Bergeal M, Binnie M, Bouillot A, et al. Development of a series of kynurenine 3-monooxygenase inhibitors leading to a clinical candidate for the treatment of acute pancreatitis. J Med Chem. 2017; 60(8): 3383-404.
doi: 10.1021/acs.jmedchem.7b00055 pmid: 28398044 |
| 27 | Li J, Zhao XL, Liu YX, Peng XH, Zhu SF, Guo H, et al. 1HNMR-based metabolomic profile of rats with experimental acute pancreatitis. BMC Gastroenterol. 2014;14: 115. |
| 28 | Chu YX, Zhang C, Xie M. Beta-hydroxybutyrate, friend or foe for stressed hearts. Front Aging. 2021;2: 681513. |
| 29 | Ouyang D. Metabolomic characterization of human pancreatitis by 1H-NMR spectroscopy. Hepatogastroenterology. 2012; 59(118):2314-7. |
| 30 | Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science. 2019; 366(6463): eaar5551. |
| 31 | Fu PF, Ramchandran R, Dudek SM, Parinandi NL, Natarajan V. Regulation of vascular endothelial barrier integrity and function by lipid-derived mediators. Cardiovasc Signal Health Dis. 2022:445-84. |
| 32 |
Fu F, Li WM, Zheng XY, Wu YL, Du D, Han CX. Role of sphingosine-1-phosphate signaling pathway in pancreatic diseases. Int J Mol Sci. 2024; 25(21): 11474.
doi: 10.3390/ijms252111474 |
| 33 |
Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014; 510(7503): 58-67.
doi: 10.1038/nature13475 |
| 34 |
Wang CH, Lai YH, Kuo CH, Lin YL, Tsai JP, Hsu BG. Association between serum indoxyl sulfate levels and endothelial function in non-dialysis chronic kidney disease. Toxins (Basel). 2019; 11(10): 589.
doi: 10.3390/toxins11100589 |
| 35 | Lusczek ER, Paulo JA, Saltzman JR, Kadiyala V, Banks PA, Beilman G, et al. Urinary 1H-NMR metabolomics can distinguish pancreatitis patients from healthy controls. JOP. 2013; 14(2): 161-70. |
| 36 | Melamed ML, Plantinga L, Shafi T, Parekh R, Meyer TW, Hostetter TH, et al. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. BMC Nephrol. 2013;14: 134. |
| 37 | Lu CL, Zheng CM, Lu KC, Liao MT, Wu KL, Ma MC. Indoxyl-sulfate-induced redox imbalance in chronic kidney disease. Antioxidants (Basel). 2021; 10(6): 936. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
